Seven Eight Capital’s Juno Therapeutics, Inc. JUNO Stock Holding History

Seven Eight Capital’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-45,532	Closed	-$2.08M	–	623
2017 Q4	$2.08M	Buy	+45,532	New	+$2.27M	0.21%	171
2016 Q3	–	Sell	-1,001	Closed	-$38K	–	628
2016 Q2	$38K	Sell	1,001 -1,500	-60%	-$62.3K	0.01%	467
2016 Q1	$95K	Buy	2,501 +600	+32%	+$20.9K	0.04%	399
2015 Q4	$84K	Buy	1,901 +1,900	+190,000%	+$94.2K	0.06%	381
2015 Q3	$0	Sell	1 -2,267	-100%	-$99.4K	﹤0.01%	738
2015 Q2	$121K	Buy	2,268 +2,218	+4,436%	+$118K	0.14%	238
2015 Q1	$3K	Buy	+50	New	+$2.43K	0.01%	431

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Seven Eight Capital's JUNO Position: Q1 2018 in Review

Seven Eight Capital sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 45,532 shares — an estimated $2.08M sold.

Seven Eight Capital first reported a position in JUNO in Q1 2015 and held it in 7 quarters. The position peaked at $2.08M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Seven Eight Capital reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Seven Eight Capital sold 45,532 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $2.08M.
Seven Eight Capital first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 7 quarters.
Seven Eight Capital's Juno Therapeutics, Inc. position peaked at $2.08M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Seven Eight Capital's 13F filing for Q1 2018, filed 14 May 2018.